Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | ITGAL | P20701 | 1/20 | 0.46 |
| ▸ | RARA | P10276 | 4/20 | 0.42 |
| ▸ | RARB | P10826 | 4/20 | 0.42 |
| ▸ | RARG | P13631 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520940 | 0.88 | ITGB2 (0.43) | ITGB2ICAM1ITGALRARARARB | |
| SCHEMBL24162776 | 0.82 | ITGB2 (0.44) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL17729317 | 0.80 | ITGB2 (0.43) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL30403463 | 0.80 | ITGB2 (0.43) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL321566 | 0.78 | NOTUM (0.42) | ITGB2ICAM1ITGALRARARARB | |
| SCHEMBL19852199 | 0.78 | ITGB2 (0.50) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL22426762 | 0.77 | ITGB2 (0.40) | ITGB2ICAM1ITGALRARARARB | |
| SCHEMBL22755210 | 0.77 | ITGB2 (0.40) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL29332746 | 0.77 | ITGB2 (0.40) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL6127888 | 0.77 | ITGB2 (0.40) | ITGB2ICAM1ITGALSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20230350294-A1 | Negative Photosensitive Resin Composition, Patterning Process, Interlayer Insulating Film, Surface Protection Film, And Electronic Component | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230350294-A1 | Negative Photosensitive Resin Composition, Patterning Process, Interlayer Insulating Film, Surface Protection Film, And Electronic Component | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023014943-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022006331-A2 | PYRIDINE-1,5-DIONES EXHIBITNG MNK INHIBITION AND THEIR METHOD OF USE | 4E THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-06-03 | — | — | US | disclosed |
| US-4829080-A | SKIN DISORDERS, PSORIASIS, ACNE | L'OREAL (FR) | 1989-05-09 | — | — | US | disclosed |
| US-4826984-A | Heteroarotinoid compounds as anticancer agents | THE BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGE ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIVERSITY (US) | 1989-05-02 | — | — | US | disclosed |
| US-4810804-A | PSORIASIS | ALLERGAN, INC. (US) | 1989-03-07 | — | — | US | disclosed |
| US-4808597-A | Method for inhibiting the degradation of cartilage | PFIZER INC. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0130795-B1 | CARBOXYLIC ACID DERIVATIVES USEFUL FOR INHIBITING THE DEGRADATION OF CARTILAGE | PFIZER INC. (US) | 1988-11-23 | — | — | EP | disclosed |
| EP-0290130-A1 | Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid like activity | ALLERGAN, INC (US) | 1988-11-09 | — | — | EP | disclosed |
| EP-0284288-A1 | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC (US) | 1988-09-28 | — | — | EP | disclosed |
| EP-0155940-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-10-02 | — | — | EP | disclosed |
| WO-1985000806-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-02-28 | — | — | WO | disclosed |
| EP-0130795-A2 | Carboxylic acid derivatives useful for inhibiting the degradation of cartilage | PFIZER INC. (US) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | ITGB2 2588/4885ICAM1 4575/4885ITGAL 3528/4885 |
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, CDYL2 | ITGB2 2501/4885ICAM1 4617/4885ITGAL 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.